SECOND AMENDMENT TO LOAN AGREEMENTLoan Agreement • June 21st, 2022 • LumiraDx LTD • Pharmaceutical preparations • New York
Contract Type FiledJune 21st, 2022 Company Industry JurisdictionThis SECOND AMENDMENT TO LOAN AGREEMENT (this “Second Amendment”), dated and effective as of June 17, 2022 (the “Amendment Effective Date”), is made by and among LUMIRADX INVESTMENT LIMITED, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (as “Borrower” and a Credit Party), BIOPHARMA CREDIT PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190 (as the “Collateral Agent”), BPCR LIMITED PARTNERSHIP, a limited partnership established under the laws of England and Wales with registration number LP020944 (“BPCR”) and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (“BioPharma Credit” and together with BPCR, the “Lenders” and each a “Lender”).